The liver is a complex and critically important organ involved in both the biosynthesis of as well as the metabolism of numerous biochemical products. Acquired metabolic liver disorders result from the loss of this hepatic homeostasis. It is thought that the first recognition of a metabolic liver disorder was the description of porphyria by Hippocrates. The focus of this chapter is the potential origins for, diagnosis of, and treatment of acquired metabolic liver disorders, which include ornithine transcarbamylase deficiency, porphyria, hemochromatosis, and alpha 1 antitrypsin deficiency. Origins for acquired metabolic liver disorders include bariatric surgery with regards to ornithine transcarbamylase deficiency, organic chemical exposure with regards to porphyria, alcohol use/repeated blood transfusions/excessive oral iron supplements/hepatitis C with regards to hemochromatosis, and infectious Tropical Pulmonary Eosinophilia with regards to alpha 1 antitrypsin deficiency. Wilson disease is an additional, important genetic metabolic liver disease. In future work, pathophysiological mechanisms of disease and preventing the development of acquired metabolic liver disorders remain areas of focus for clinical research in this field.
KeywordsMetabolic disease Ornithine transcarbamylase deficiency Hemochromatosis Porphyria Wilson disease Alpha 1 antitrypsin deficiency
- 1.Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Linder M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.CrossRefGoogle Scholar
- 2.Brassier A, Gobin S, Arnoux JB, Valayannopoulos V, Habarou F, Kossorotoff M, Servais A, Barbier V, Dubois S, Touati G, Barouki R, Lesage F, Dupic L, Bonnefont JP, Ottolenghi C, De Lonlay P. Long-term outcomes in ornithine transcarbamylase deficiency: a series of 90 patients. Orphanet J Rare Dis. 2015;10:58. https://doi.org/10.1186/s13023-015-0266-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ, Porphyrias Consortium of the Rare Diseases Clinical Research Network. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66(4):1314–22.CrossRefGoogle Scholar
- 19.Li H, Liu L, Li Y, He S, Liu Y, Li J, Tao R, Li W, Shang S. Familial screening of children with Wilson disease: necessity of screening in previous generation and screening methods. Medicine. 2018 Jul;97(27):e11405. https://doi.org/10.1097/MD.0000000000011405.CrossRefPubMedPubMedCentralGoogle Scholar
- Gattermann N. The treatment of secondary hemochromatosis. Deutsches Ärzteblatt Int. 2009;106(30):499–504.Google Scholar